Although GLP-1 analogs with a longer half-life are currently being investigated in clinical trials for the treatment of NAFLD, we hypothesized that increasing endogenous GLP-1 levels would induce sufficient stimulus to treat NAFLD and thus, we could reach therapeutically relevant levels without the need for a long half-life peptide. The gene discussed is GCG; the disease is metabolic dysfunction-associated steatotic liver disease.